Pharmaceutical composition for treating myocardial infarction

A technology of acute myocardial infarction and composition, applied in the field of pharmaceutical composition for the treatment of myocardial infarction, can solve the problems of increased mortality rate of model rats, reduction of infarct size of model rats of acute myocardial infarction, etc., and achieve reduction of toxic and side effects in vivo and in vitro , reduce the size of myocardial infarction, and enhance the effect of myocardial protection

Active Publication Date: 2017-09-15
CHINA PHARM UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The inventor's research group also confirmed this in vitro cytotoxicity, and also confirmed the in vivo toxicity of these four tanshinone compounds, which not only reduced the infarct size of the acute myocardial infarction model rats, but also obviously led to the death of the model rats Elevated rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating myocardial infarction
  • Pharmaceutical composition for treating myocardial infarction
  • Pharmaceutical composition for treating myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Embodiment 1: the attenuation effect of protocatechualdehyde to dihydrotanshinone I

[0060] 1. Experimental materials

[0061] 1.1 Instruments and equipment

[0062] Ultra-clean bench (Thermo Scientific 1300A2, USA); multifunctional microplate reader FLUOstar Omega (BMG LABTECH, Germany); electronic scale (Tianjin Tianma Hengji Instrument Co., Ltd.); Sartorius analytical balance (Beijing Doris Balance Co., Ltd.); BL -420S biological function experiment system (Chengdu Taimeng Technology Co., Ltd.); HX-100E small animal ventilator (Chengdu Taimeng Technology Co., Ltd.); HW-1000 water bath (Chengdu Taimeng Technology Co., Ltd.).

[0063] 1.1 Reagents

[0064] Standard products: dihydrotanshinone I and protocatechualdehyde were purchased from Chengdu Mansite Biotechnology Co., Ltd.

[0065] Reagents: DMEM high glucose medium, fetal bovine serum, 100× penicillin and streptomycin (Thermo Fisher, USA); type II collagenase (Worthington, USA); 5-bromodeoxyuridine (sigma, ...

Embodiment 2

[0127] Embodiment 2: the synergistic effect of protocatechualdehyde and dihydrotanshinone I

[0128] 1.1 Instruments and equipment

[0129] Multifunctional microplate reader FLUOstar Omega (BMG LABTECH, Germany); 80-2 desktop low-speed centrifuge (Shanghai Medical Instrument (Group) Co., Ltd. Surgical Instrument Factory); 5804R desktop refrigerated high-speed centrifuge (Eppendorf, Germany); Sartorius analysis Balance (Beijing Doris Balance Co., Ltd.) electronic scale (Tianjin Tianma Hengji Instrument Co., Ltd.); Sartorius analytical balance (Beijing Doris Balance Co., Ltd.); BL-420S biological function experiment system (Chengdu Taimeng Technology Co., Ltd.); HX- 100E small animal ventilator (Chengdu Taimeng Technology Co., Ltd.); HW-1000 water bath (Chengdu Taimeng Technology Co., Ltd.).

[0130] 1.2 Reagents

[0131] Standard products: dihydrotanshinone I, protocatechualdehyde, all purchased from Chengdu Mansite.

[0132] Reagents: urethane (Sinopharm Chemical Reagent Co...

Embodiment 3

[0156] Embodiment 3: Danshensu (DSS) to the attenuation and synergistic effect of Tanshinone I (TI)

[0157] The experimental materials and experimental methods are the same as those in Example 1 and Example 2, and the experimental results are as follows.

[0158] 1. In vitro study on the cytotoxicity of tanshinone I and the attenuation of tanshenin

[0159] The primary cardiomyocytes of suckling rats were treated with tanshinone I for 24 hours, and the cell viability was measured after 1 week of culture. The experimental results showed that when the concentration of tanshinone I was higher than 2 μM, there was a certain cytotoxic effect (compared with the control group, P Figure 10 and Table 6. When the administration concentration of tanshinone I was 4 μM, different concentrations of danshensu were given. When the concentration of danshinone was higher than 37.5 μM, the cell death caused by tanshinone I could be effectively reversed (P Figure 11 and Table 7.

[0160] Tabl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating myocardial infarction. The pharmaceutical composition comprises a tanshinone compound shown in a formula (I) and a phenolic acid compound containing one or more substituent shown in a formula (II), preferably, comprises tanshinone I and tanshinol or tanshinone IIA and salvianolic acid B or dihydrotanshinone I and protocatechualdehyde or cryptotanshinone and salvianolic acid C. According to the invention, the phenolic acid compound containing the specific substituent and the tanshinone compound having a specific structure are prepared to obtain the pharmaceutical composition. The pharmaceutical composition can effectively reduce the myocardial infarction area of mice with acute myocardial infarction, and has low toxic and side effects; the phenolic acid compound in the composition can obviously reduce the in vitro and vivo toxic and side effects of the tanshinone compound, and can enhance the cardiac muscle protection effect of the tanshinone compound on the mice with acute myocardial infarction.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a combined medicine of known chemical components, in particular to a pharmaceutical composition for treating myocardial infarction. Background technique [0002] Acute myocardial infarction (AMI) is the most serious coronary artery disease, accounting for one-third of the annual deaths in developed countries. In the United States, more than 2.4 million people died of myocardial infarction, and in Europe and northern Asia, more than 4 million people died of myocardial infarction [Worldwide trends in bloodpressure from 1975 to 2015: apooled analysis of 1479 population-based measurement studies with 19 1 million participants, Lancet. 2016 Nov 15.pii:S0140-6736(16)31919-5]. In recent decades, percutaneous coronary intervention or thrombolytic therapy has been used to reduce the mortality rate of coronary heart disease. Drugs are mostly used for secondary prevention. Currently, the clinically u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/343A61K31/192A61K31/11A61P9/10
CPCA61K31/11A61K31/192A61K31/343A61K31/58A61K2300/00
Inventor 李萍郝海平倪丽红蒋黎锋杨华祁励丰荣曾昊夏露丹
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap